PriceTargets.com logo

Shattuck Labs - STTK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.78
  • Forecasted Upside: 114.03%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 2 Strong Buy Ratings
$5.97 As of 09/15/2026 05:00 PM ET
▼ -0.23 (-3.71%)

This chart shows the closing price for STTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shattuck Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STTK

Analyst Price Target is $12.78
▲ +114.03% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Shattuck Labs in the last 3 months. The average price target is $12.78, with a high forecast of $18.00 and a low forecast of $7.00. The average price target represents a 114.03% upside from the last price of $5.97.

This chart shows the closing price for STTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Shattuck Labs. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 2 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2026
  • 2 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 2 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/11/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/24/2026Raymond James FinancialInitiated CoverageStrong-Buy$18.00
8/24/2026Raymond James FinancialInitiated CoverageStrong-Buy$18.00
8/24/2026TD CowenUpgradeStrong-Buy
8/11/2026HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $14.00
7/24/2026JPMorgan Chase & Co.Initiated CoverageOverweight$10.00
7/20/2026Leerink PartnersInitiated CoverageOutperform$16.00
6/16/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
6/8/2026Needham & Company LLCBoost TargetBuy ➝ Buy$14.00 ➝ $17.00
6/8/2026HC WainwrightReiterated RatingBuy ➝ Buy$18.00
6/5/2026Jefferies Financial GroupUpgradeOutperform$7.00
6/5/2026CitigroupUpgradeNeutral ➝ Buy$7.00
6/2/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
5/19/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
5/8/2026WedbushBoost TargetOutperform ➝ Outperform$8.00 ➝ $11.00
4/27/2026Cantor FitzgeraldInitiated CoverageOverweight
4/20/2026HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $18.00
3/13/2026CitigroupBoost TargetNeutral ➝ Neutral$4.00 ➝ $7.00
3/6/2026TD CowenReiterated RatingBuy ➝ Buy
3/6/2026Needham & Company LLCInitiated CoverageHold ➝ Buy$25.00
3/6/2026WedbushBoost TargetOutperform ➝ Outperform$4.00 ➝ $8.00
1/28/2026Piper SandlerInitiated CoverageOverweight$15.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/6/2026CitigroupBoost TargetNeutral ➝ Neutral$2.00 ➝ $4.00
12/1/2025HC WainwrightUpgradeNeutral ➝ Buy$6.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/8/2025WedbushInitiated CoverageOutperform$4.00
8/14/2025Leerink PartnersLower TargetOutperform ➝ Outperform$4.00 ➝ $2.00
8/14/2025Needham & Company LLCReiterated RatingHold ➝ Hold
3/27/2025Needham & Company LLCReiterated RatingHold ➝ Hold
3/27/2025HC WainwrightReiterated RatingNeutral ➝ Neutral
3/17/2025Leerink PartnersUpgradeStrong-Buy
3/17/2025Leerink PartnersInitiated CoverageOutperform$4.00
11/15/2024HC WainwrightReiterated RatingNeutral
11/14/2024Needham & Company LLCReiterated RatingHold
10/2/2024EvercoreUpgradeStrong-Buy
10/2/2024CitigroupDowngradeBuy ➝ Neutral$8.00 ➝ $2.00
10/2/2024Needham & Company LLCDowngradeBuy ➝ Hold$8.00
10/1/2024HC WainwrightDowngradeBuy ➝ Neutral
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
8/15/2024CitigroupLower TargetBuy ➝ Buy$9.00 ➝ $8.00
8/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
8/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
6/20/2024HC WainwrightLower TargetBuy ➝ Buy$28.00 ➝ $16.00
6/17/2024CitigroupLower TargetBuy ➝ Buy$10.00 ➝ $9.00
6/17/2024BTIG ResearchDowngradeBuy ➝ Neutral
6/14/2024Needham & Company LLCLower TargetBuy ➝ Buy$12.00 ➝ $8.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
5/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
5/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
5/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
3/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
2/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
2/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
8/11/2023Needham & Company LLCLower TargetBuy ➝ Buy$14.00 ➝ $12.00
4/20/2023Needham & Company LLCReiterated RatingBuy$14.00
4/20/2023HC WainwrightReiterated RatingBuy$28.00
4/3/2023HC WainwrightReiterated RatingBuy$28.00
3/9/2023CitigroupLower Target$13.00 ➝ $9.00
2/24/2023HC WainwrightReiterated RatingBuy$28.00
2/24/2023Needham & Company LLCLower TargetBuy$21.00 ➝ $14.00
2/13/2023HC WainwrightReiterated RatingBuy$28.00
8/31/2022BTIG ResearchInitiated CoverageBuy$12.00
8/12/2022Needham & Company LLCLower TargetBuy$31.00 ➝ $21.00
6/3/2022HC WainwrightReiterated RatingBuy$28.00
6/1/2022CitigroupInitiated CoverageBuy$13.00
5/2/2022HC WainwrightInitiated CoverageBuy$28.00
3/16/2022Needham & Company LLCLower TargetBuy$46.00 ➝ $31.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 5 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
6/18/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Shattuck Labs logo
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $5.97
Low: $5.91
High: $6.23

50 Day Range

MA: $7.06
Low: $5.97
High: $8.06

52 Week Range

Now: $5.97
Low: $1.70
High: $8.33

Volume

895,232 shs

Average Volume

748,749 shs

Market Capitalization

$599.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Shattuck Labs?

The following sell-side analysts have issued stock ratings on Shattuck Labs in the last year: Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Piper Sandler, Raymond James Financial, Inc., TD Cowen, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for STTK.

What is the current price target for Shattuck Labs?

0 Wall Street analysts have set twelve-month price targets for Shattuck Labs in the last year. Their average twelve-month price target is $12.78, suggesting a possible upside of 114.0%. Raymond James Financial, Inc. has the highest price target set, predicting STTK will reach $18.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $7.00 for Shattuck Labs in the next year.
View the latest price targets for STTK.

What is the current consensus analyst rating for Shattuck Labs?

Shattuck Labs currently has 1 sell rating, 9 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STTK will outperform the market and that investors should add to their positions of Shattuck Labs.
View the latest ratings for STTK.

What other companies compete with Shattuck Labs?

Other companies that are similar to Shattuck Labs include SELLAS Life Sciences Group, Nektar Therapeutics, Sarepta Therapeutics, Palvella Therapeutics and Aurinia Pharmaceuticals. Learn More about companies similar to Shattuck Labs.

How do I contact Shattuck Labs' investor relations team?

Shattuck Labs' physical mailing address is 500 W. 5th Street, Austin, TX, 78701. The company's listed phone number is 512-900-4690 and its investor relations email address is [email protected]. The official website for Shattuck Labs is www.shattucklabs.com. Learn More about contacing Shattuck Labs investor relations.